Salvato in:
| Autori principali: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2024
|
| Soggetti: | |
| Accesso online: | https://onlinelibrary.wiley.com/doi/10.1111/ctr.15462 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Sommario:
- A Multi‐Center International Analysis of Lung Transplantation Outcomes in Patients With COVID‐19 Mohammed Abul Kashem Gabriel Loor Amir Emtiazjoo Matthew Hartwig Dirk Van Raemdonck Hannah Calvelli Andres Leon Pena Marcelo Salan‐Gomez Huaqing Zhao Michael Warnick Mauricio Villavicencio Fabio Ius Kamrouz Ghadimi Jawad Salman Satish Chandrashekaran Tiago Machuca Pablo G. Sanchez Kathirvel Subramaniam Arne Neyrinck Stephen Huddleston Laurens Ceulemans Asishana Osho Ethan D'Silva Uma Ramamurthy Andrew Shaffer Nathaniel Langer Yoshiya Toyoda Clinical Transplantation ABSTRACTIntroductionLung transplantation has become increasingly utilized in patients with COVID‐19. While several single‐center and UNOS database studies have been published on lung transplants (LTs) for end‐stage lung disease (ESLD) from Coronavirus disease 2019 (COVID‐19), there is a lack of multi‐center and international data.MethodsThis is a multicenter analysis from 11 high‐volume lung transplant centers in the United States and Europe. Data were collected through the Multi‐Institutional ECLS Registry and stratified by ESLD due to COVID‐19 versus other etiologies. Demographics and clinical variables were compared using Chi‐square test and Fisher's exact test. Survival was assessed by Kaplan‐Meier curves and compared by log‐rank test with propensity score matching.ResultsOf 1606 lung transplant recipients, 46 (2.9%) were transplanted for ESLD from COVID‐19 compared to 1560 (97.1%) without a history of COVID‐19. Among COVID‐19 patients, 30 (65.2%) had COVID‐19‐associated ARDS and 16 (34.8%) had post‐COVID‐19 fibrosis. COVID‐19 patients had higher lung allocation scores (78.0 vs. 44.4, p < 0.0001), had severely limited functional status (37.0% vs. 2.9%, p < 0.0001), had higher preoperative ECMO usage (65.2% vs. 5.4%, p < 0.0001), and spent less time on the waitlist (32 vs. 137 days, p < 0.0001). A 30‐day survival was comparable between COVID‐19 and non‐COVID‐19 patients before (100% vs. 98.7%, p = 0.39) and after propensity matching (p = 0.15).ConclusionsPatients who received LTs due to COVID‐19 had short‐term survival comparable to that of patients without COVID‐19. Our findings support the idea that lung transplantation should be considered for select patients with ESLD due to COVID‐19. 10.1111/ctr.15462 http://onlinelibrary.wiley.com/termsAndConditions#vor